Rosmarinus officinalis L.: an update review of its phytochemistry and biological activity

Joana M Andrade1, Célia Faustino2, Catarina Garcia1, Diogo Ladeiras1, Catarina P Reis2,3 & Patricia Rijo*,1,2

1CBIOS – Research Center for Biosciences & Health Technologies, Universidade Lusófona de Humanidades e Tecnologias, Campo Grande 376, 1749–024 Lisboa, Portugal
2iMed.ULisboa – Research Institute for Medicines, Faculdade de Farmácia da Universidade de Lisboa, Av. Prof. Gama Pinto, 1649–003 Lisboa, Portugal
3Biophysics & Biomedical Engineering Institute (IBEB), Faculdade de Ciências da Universidade de Lisboa, Campo Grande, 1749–016 Lisbon, Portugal

* Author for correspondence: Tel.: +351 217 515 500; patricia.rijo@ulusofona.pt

The worldwide interest in the use of medicinal plants has been growing, and its beneficial effects being rediscovered for the development of new drugs. Based on their vast ethnopharmacological applications, which inspired current research in drug discovery, natural products can provide new and important leads against various pharmacological targets. This work pioneers an extensive and an updated literature review on the current state of research on Rosmarinus officinalis L., elucidating which compounds and biological activities are the most relevant. Therefore, a search was made in the databases PubMed, ScienceDirect and Web of Science with the terms ‘rosemary’, ‘Rosmarinus officinalis’, ‘rosmarinic acid’ ‘carnosol’ and ‘carnosic acid’, which included 286 articles published since 1990 about rosemary’s pharmacological activities and their isolated compounds. According to these references, there has been an increasing interest in the therapeutic properties of this plant, regarding carnosic acid, carnosol, rosmarinic acid and the essential oil. The present manuscript provides an updated review upon the most reported activities on R. officinalis and its active constituents.

Lay abstract: The worldwide interest in the use of medicinal plants has been growing, and their beneficial effects being rediscovered for the development of new drugs. Actually, current research in drug discovery has been inspired on the vast ethnopharmacological applications of natural products, providing new and important leads against various pharmacological targets.

In this work, an updated literature review is presented to clarify the current state of research on Rosmarinus officinalis L., elucidating its constituents and their most relevant biological activities. Therefore, this work provides an updated review upon the most reported medicinal properties, namely, antitumoral, anti-inflammatory, analgesic, neurodegenerative, endocrinal, anti-infective and antioxidant.

First draft submitted: 16 October 2017; Accepted for publication: 21 December 2017; Published online: 1 February 2018

Keywords: biologic activity • carnosic acid • carnosol • essential oil • rosemary • rosmarinic acid • Rosmarinus officinalis

Medicinal plants have been used worldwide by indigenous populations, playing an important role in the treatment of human and animal diseases [1]. More recently, the majority of modern drugs have been developed from isolated compounds of medicinal plants, based on their ethnopharmacological uses/applications [1–5].

The role of natural products on drug development has been increasing, not only when the bioactive compounds are directly used as therapeutic agents but also when they are used as raw material for drug synthesis, or as a base model for new biologically active compounds [6,7]. However, validating and using plants as a phytopharmaceutical requires a great deal of basic and applied research, in order to set this resource at the same level of importance of conventional pharmaceutical products [1].
Moreover, only about 10% of 250,000 species of plants estimated worldwide have been scientifically studied with potential use in healthcare [8,9]. Also, around 60,000 species will probably become extinct by the year of 2050, so it is urgent to search for new compounds with therapeutic interest [3].

*Rosmarinus officinalis* L. is a medicinal plant that belongs to the *Lamiaceae* family and is commonly known as rosemary [10]. Besides the culinary uses due to the characteristic aroma, this plant is also widely employed by indigenous populations, where it grows wild [4].

The extracts obtained from rosemary are used as a natural antioxidant, improving the shelf life of perishable foods [5]. In fact, the EU has approved the rosemary extract (E392) as a safe and effective natural antioxidant for food preservation [11].

Due to the growing interest on the medicinal properties of *R. officinalis* L., it is of great importance to review previous studies, establish professional links between the companies, government, the major pharmaceutical corporations and academic institutions [6,12–14]. Therefore, this manuscript builds a literature gathering on rosemary, an endemic species in Portugal to identify main bioactive compounds, extracts and essential oils and their connection with pharmacological activities. Also, it is intended to promote the development and expansion of this plant-based medicine (PBM), promoting a conscious exploitation of biodiversity as a source of chemical compounds and their use in the development of new lead drugs.

**Research method**

A search was made with the databases PubMed, ScienceDirect and Web of Science for an update on rosemary pharmacological activities and main constituents. The search was performed using the terms ‘rosemary’, ‘*Rosmarinus officinalis*’, ‘rosmarinic acid’, ‘carnosol’ and/or ‘carnosic acid’, published since 1990.

**Inclusion & exclusion criteria**

The search for this review was solely performed on English, Spanish and Portuguese languages since 1990, reporting pharmacological and chemical data, and some experimental studies on animals, using the isolated compounds, extracts and/or essential oils from *R. officinalis*. Finally, in order to grant reliability, only publications on peer-reviewed journals were chosen.

**Medicinal plants as a source of natural products**

PBM has been employed throughout history and is nowadays the foundation of traditional medicine. Plants can be used as therapeutic resources in the form of herbal infusion, pharmaceutical preparations such as extracts, tablets or capsules by extracting and purifying active compounds [12,15]. Primitive communities in China, India and many other countries learned from experience [16] to distinguish the useful plants with beneficial effects, from those which were toxic or inactive, and to identify which combinations of plants were best for each illness [17].

Traditional medicine can be broadly classified into four basic systems: the Ayurvedic medicine (meaning ‘science of life’), which originated in India more than 5000 years ago; Chinese medicine, which is a part of traditional oriental medicine; African medicine; and Western medicine, originally from Greece and Rome, then spreading to Europe and to North and South America [17]. Ayurvedic medicine continues to be one of the oldest traditional medicine systems currently practiced in India, Sri Lanka and other countries, with over 1000 plants described in the Ayurvedic Pharmacopoeia [12,18]. There are several ancient records on the use of plants such as the *Ebers Papyrus* (1550 BC) and *De Materia Medica*, written by Dioscorides (77 AD). This last one describes over 600 medicinal plants, but during the Middle Ages, there was very little progress in the development of PBM [19].

Medicinal plants have an important role on pharmacological research and drug development, not only when the bioactive compounds are directly used as therapeutic agents, but also when they are used as raw material for drug synthesis or as a base model for new lead compounds [6,7]. However, validating this resource at the same level of conventional pharmaceutical products requires a great deal of basic and applied research [1].

A phytopharmaceutical preparation, or a PBM is any drug obtained exclusively from plants, in both raw and pharmaceutical formulation [15]. In many countries, PBMs are not regulated or controlled leading to poor quality control, consequently decreasing the acceptance and confidence in these products by the medical community [4,6–7].

In 1805, morphine became the first pure pharmacologically active compound to be isolated from a plant, although it was only in 1923 that its structure was elucidated [16]. Still in the 19th century, the first organic synthesis of urea, by Friedrich Wohler in 1828 [20], initiated the era of synthetic compounds. Even though synthetic drug development became the mainstay of conventional medicine [6], numerous alkaloids were isolated,
such as atropine (*Atropa belladonna*), cocaine (*Erythroxylum coca*), ephedrine (species *Ephedra*), codeine (*Papaver somniferum*), pilocarpine (*Pilocarpus jaborandi* Holmes) and physostigmine (*Physostigma venenosum*), that are still widely used in drug prescription [16]. However, the interest in PBM for drug development was only restored in the early 1980s [6], due to the ineffectiveness of conventional medicine, namely: the cytotoxicity and side effects; the discomfort in the treatment of chronic diseases, in comparison with the use of phytopharmaceuticals; the abuse and misuse of synthetic drugs; the unavailable pharmacological treatments in a large percentage of the world population; and more importantly, the high costs involved in conventional medicine [2,4,11–13].

In 1997, the world market on medicinal products, not subject to medical prescription was 10 billion dollars, with an annual growth of 6.5% [12]. In 2001 and 2002, about a quarter of the top-selling drugs in the world were from natural products or their derivatives [21]. In 2003, the growth exceeded expectations, achieving sales of over 65 billion dollars, with 9 billion in Europe, with Germany as the European leader [12]. In fact, the use of the rosemary leaf has been approved by the German Commission for dyspepsia, high blood pressure and rheumatism at doses of 4–6 g/day, while the essential oil has been approved at doses of 0.1–1 ml [10]. In 2009, the total market value for PBM was about 83 billion dollars [9].

In accordance with the principles of phytotherapy, a plant contains a number of pharmacologically active compounds which must be seen as a single unit [22]. The entire extract can be standardized and clinically tested for a particular clinical condition. This feature differentiates phytotherapy from conventional pharmacotherapy [12]. Chemically speaking, natural compounds can lead to the active substances, not only allowing the planning and design of new drugs, but can also lead to the development of biomimetic synthesis (used as precursors) [23,24].

Although the industrial revolution and the development of organic chemistry have resulted in a preference for synthetic products, the WHO reports that in most of the developing countries about 80% of citizens still depend on the traditional medicine as main source of healthcare [25]. Nonetheless 25% of all prescribed drugs worldwide are derived from plants [17–18,26–27].

Presumably the production of phytotherapy drugs will require genetically uniform plants monocultures, grown in fully controlled conditions ensuring consistency and biochemical optimization of safety and efficacy of these products [28]. It is necessary to develop innovative technologies for isolation, purification and structural characterization for improved discovery and development of new PBMs [13,18,28].

**Medicinal plants as a source for drug development**

Medicinal plants are a renewable source of compounds, providing an almost unlimited source of new and complex chemical structures [26,29]. Only some of these compounds were investigated or produced as synthetic drugs, such as vinblastine, vincristine, taxol and digoxin [26,29]. Examples of the discovery of new molecules from isolated compounds are irinotecan and topotecan (anticancer molecules), derived from an isolated compound from *Camptotheca* spp. and thereafter from *Mappia* spp. (*camptothecin*) [30].

Therefore, plants provide a desirable therapeutic effect with reduced risk of iatrogenic complications, such as side effects often associated with conventional medication [23]. The combined treatment of herbal medicines and synthetic drugs may reduce some adverse effects of highly potent drugs [23].

However, a major limitation on the use of plants in the phytopharmaceutical area is the lack consistency in the levels of compounds present in the extract due to natural variability, leading to inconsistent results upon scientific validation [31]. Also, a major limitation is the lack of reproducibility of the activity by more than 40%, when using plant extracts, as the activity detected often do not occur when the samples are re-extracted [27–28,32]. This problem is largely due to differences in the biochemical profiles of plants harvested at different times and locations, variations in the same genus plant and variations in the methods used for the extraction and determination of biological activity [28,32–33].

Drug development from medicinal plants faces yet another challenge. The bioactive compounds are generally isolated in small quantities, being insufficient for all stages of development and production of a new drug [16,18,21]. Therefore, the collaboration between researchers in different areas is essential to determine whether the total synthesis or semisynthesis is possible from the active compound.

Moreover, the effectiveness and activity of a phytochemical sample does not often result from the action of only one compound which is linked to the natural variability, already discussed, but from a synergic effect of several compounds (e.g., *Panax ginseng*) [28,32–33]. In most cases, this limitation leads to different results, which are difficult to interpret and to be accepted by the scientific community.
Regarding the lack of regulation, PBMs can be adulterated and contaminated in countries where purity and quality control are negligent [12,32]. In many cases, these adulterated products can cause significant health problems [32]. Ayurvedic products are often prepared with inorganic active compounds, which when combined with environmental pollution (such as pesticides), can increase the content of heavy metals above the permissible limits [32].

Standardization defined as the normalization of a sample that can have a minimal amount of one or more compounds is yet another setback [9]. Unfortunately, phytotherapy rarely satisfies the standardization norms [32,34]. This is mainly due to the lack of information about pharmacologically active compounds, and to the plants not being grown in a controlled environment [32,34]. The variability of the content and concentration of constituents in a plant, together with the various extraction and processing techniques used by different manufacturers, lead to variability in the content and quality of marketed PBM [23,29,32,34]. The consistency in composition and biological activity are prerequisites for the safe and effective use of therapeutic products [23,32].

**Lamiaceae family**

Rosemary belongs to the *Lamiaceae* family, which is one of the largest and most distinguished families of flowering plants, including about 236 genera and 6900–7200 species worldwide [35,36]. The original family name is *Labiatae* because the flowers typically have petals fused into top and bottom lips, although currently most botanists use the name *Lamiaceae* [36].

The *Lamiaceae* is well known for its biologically active essential oils, common to many family members, its ornamental and culinary herbs such as basil, lavender, mint, rosemary, sage and thyme [35,37].

Several studies report the presence of a wide variety of compounds such as terpenes, iridoids, flavonoids and phenolic compounds in plants of the family. The *Lamiaceae* family includes species of plants containing large amounts of phenolic acids, such as rosmarinic acid, which have antibacterial, antiviral, antioxidant and anti-inflammatory properties [35].

Many species of this family have been the subject of experimental studies confirming the effectiveness of some of its traditional applications. *Thymus* spp. (thyme) has antibacterial activity due to the presence of thymol and can be used as a disinfectant; lavender oil, containing terpenic compounds, is used in the treatment of dandruff and hair growth, and also has antimicrobial, antiviral and antifungal properties; the aerial parts of *Stachys lavandulifolia* Vahl. are effective in the improvement of anxiety disorders due to the presence of apigenin and luteolin in the plant; *Lavandula angustifolia* Mill is used for inflammation, cough, as a sedative and in digestive problems; and compounds such as 1,8-cineole are very common in the genus *Nepeta*, with expectorant, antiseptic and anthelmintic activities [35].

The following sections will further address an important species of the *Lamiaceae* family, *R. officinalis* L., which is very common in Portugal, mainly focusing on its biological compounds and activities.

**Rosmarinus officinalis Linnaeus**

The *R. officinalis* L. (rosemary) is one of the species in the genus *Rosmarinus* named by Carl Linnaeus (see scientific classification displayed in Table 1), and original from the temperate countries of the Mediterranean region, such as...
Rosmarinus officinalis L.: an update review of its phytochemistry & biological activity

Figure 1. Number of published papers in Rosmarinus officinalis L. since the 1990s until 30 November 2014, and the year of 2015, according to the databases searched in PubMed, ScienceDirect and Web of Science.

Table 2. Some examples of bioactive compounds that can be extracted with different solvents.

| Water   | Ethanol | Methanol | Chloroform | Dichloromethane | Ether | Acetone |
|---------|---------|----------|------------|-----------------|-------|---------|
| Anthocyanin | Tannin  | Anthocyanin | Terpenoid  | Terpenoid        | Alkaloid | Flavonoid |
| Tannin  | Polyphenol | Tannin  |Terpenoid    |                   |         |         |
| Saponin | Flavonol | Saponin  | Tannin      | Terpenoid        |         |         |
| Terpenoid | Terpenoid | Flavone  | Polyphenol  | Terpenoid        |         |         |

| Water | Ethanol | Methanol | Chloroform | Dichloromethane | Ether | Acetone |
|-------|---------|----------|------------|-----------------|-------|---------|
| Water | Ethanol | Methanol | Chloroform | Dichloromethane | Ether | Acetone |

Data taken from [45].

Portugal.

Rosemary is a dense bush, branched, evergreen and blue–white flower, reaching a height of about 1 m [39,40]. It is characterized by leaves with 1–4 cm long and 2–4 mm wide, sessile, leathery, linear to linear-lanceolate, with curved edges, dark green upper side and granulosa and page bottom tomentous, with prominent midrib, and very characteristic smell [38,40–41].

In the past 20 years, there has been a clear tendency to rise in the number of articles regarding R. officinalis L. The interest in this plant is translated into the high amount of research performed since 2010, an average of 120 each year, a number that tends to increase, as shown in Figure 1.

In order to obtain the biologically active compounds from rosemary, it is necessary to obtain the plant’s extracts and/or essential oils, and perform a phytochemical characterization. The extraction methods are applied to the plant most active portions (leaves, roots, stems or flowers), using selective solvents and standard procedures [42]. These techniques result in complex mixtures in liquid and semisolid forms or, after removal of the solvent, in the form of dry powder [43,44].

After analysis of the collected articles, the most used extraction methods to obtain the bioactive compounds from R. officinalis (see tables in Supplementary material) are maceration, hydrodistillation, distillation and Soxhlet by supercritical fluid extraction.
Figure 2. Chemical structure of three major compounds present in *R. officinalis*. (A) Carnosic acid. (B) Carnosol. (C) Rosmarinic acid.

The essential oils are complex mixtures that contain hundreds of compounds, volatiles, monoterpenes, sesquiterpenes, aromatic compounds and other derivatives [46]. The essential oil of rosemary obtained by steam distillation from the leaves (up to 2.5%) is colorless to light yellow, water-insoluble and with a characteristic aroma of camphor [38–39,41,47]. The main constituents of the rosemary essential oil are camphor (5.0–21%), 1,8-cineole (15–55%), α-pinene (9.0–26%), borneol (1.5–5.0%), camphene (2.5–12%), β-pinene (2.0–9.0%) and limonene (1.5–5.0%) in proportions that vary according to the vegetative stage and bioclimatic conditions [38,40].

Regarding the extracts, the phytochemicals mainly present in *R. officinalis* are rosmarinic acid, camphor, caffeic acid, ursolic acid, betulinic acid, carnosic acid and carnosol [19,38,40,48]. Therefore, *R. officinalis* is mainly composed of phenolic compounds, di- and triterpenes and essential oils [49,50].

In traditional medicine, the leaves of *R. officinalis* L. are used based on their antibacterial activities [51], carminative [9,38,52] and as analgesic in muscles and joints [38–40,53]. Also, rosemary's essential oils and extracts obtained from flowers and leaves are used to treat minor wounds, rashes, headache, dyspepsia, circulation problems, but also as an expectorant, diuretic and antispasmodic in renal colic [38–40,48].

Polyphenols are antioxidant chemical compounds primarily responsible for the fruit coloring, which are classified as phenolic acids, flavonoids and nonflavonoids [54]. In addition to their antioxidant properties, they play a very important role in the plant defenses against herbivores, pathogens and predators; therefore, they have an application in the control of infectious agents in humans [54]. In *R. officinalis*, the most common polyphenols are apigenin, diosmin, luteolin, *genkwanina* and phenolic acids (>3%), especially rosmarinic acid, chlorogenic acid and caffeic acid [19,37,39–40].

Other major compounds common in rosemary are terpenes, usually present in essential oils and resins, which include over 10,000 compounds divided into mono-, di-, tri- and sesquiterpenes, depending on the number of carbon atoms and isoprene groups (C5H8) [46,54]. It is possible to find in rosemary terpenes such as epirosmanol, carnosol, carnosic acid (tricyclic diterpenes: see structure in Figure 2), ursolic acid and oleanolic acid (triterpenes) [19,38,40,48].

However, the carnosic acid, which is converted to carnosol by oxidation, has physicochemical, thermal and photolabile properties, which can be avoided by a supercritical fluid extraction (low temperature operation) [55].

In 2014, five new compounds were identified in an ethanolic extract of *R. officinalis*, the officinoterpenoside A1 and A2 (diterpenoid glycosides), officinoterpeneside B and C (triterpenoid glycosides) and officinoterpenoside D (normonoterpenoid) [56].

Regarding the most studied compounds from *R. officinalis* and their biological activities, the increased pharmacological potential is clear for carnosic acid and the essential oil of rosemary. This issue will be further reviewed in the next section.

**Biological activities of *R. officinalis* compounds**

Rosemary has been widely used not only in cooking, especially to modify and enhance flavors, but also in traditional medicine, being a highly appreciated medicinal plant to prevent and cure colds, rheumatism, pain of muscles and joints [56,57]. It is nowadays one of the most popular sources of natural bioactive compounds, and in fact, this plant exerts various pharmacological activities such as antibacterial [51], antidiabetic [58], anti-inflammatory [59,60], antitumor [61–63] and antioxidant [64], among others [56].

After revising and analyzing the items of the gathered bibliographic data, the most studied compounds from *R. officinalis* were identified.
Rosmarinus officinalis L.: an update review of its phytochemistry & biological activity

**Reported R. officinalis compounds biological activity**

- Carnosic acid: 30%
- Rosmarinic acid: 27%
- Essential oil: 17%
- Carnosol: 12%
- Others: 8%
- Ursolic acid: 6%

**Figure 3.** Percentage of biological activity studies associated with each compound, from all investigated articles. Studies on the carnosic acid include the compounds 12-O-metilcarnosic acid and 12-methoxy-cis/trans-carnosic acid. Studies on the essential oil include the compounds 1,8-cineol, α-pinene and β-pinene.

The graph of Figure 3 shows that carnosic acid is the most investigated bioactive compound with about 30% of the studies, together with the essential oil, followed by carnosol, rosmarinic acid and ursolic acid, which comprised 35% of the research studies.

Compounds such as betulinic acid, oleanolic and micromeric, rosmanol, epirosmanol and luteolin, among others, have not been the target of extensive studies, corresponding only to 23 studies out of 275. However, there has been an increasing interest in these compounds since 2010 (Table 3).

There is clearly, according to the scientific community, a great pharmacological potential in *R. officinalis*, especially with carnosic acid and the essential oil, which is apparent from the increasing number of studies in the last 5 years, with 53 and 46 studies, respectively.

The biological activities of the *R. officinalis* L. have been attributed to two groups of compounds: a volatile fraction and phenolic compounds [65]. This last group mainly contains a fraction of flavonoids, rosmarinic acid and some diterpene compounds structurally derived from carnosic acid, carnosol and rosmanol [65].

From the articles reviewed, it was eminent that in the last 20 years, rosemary has been most studied considering its anticancer, antioxidant and anti-infectious properties, encompassing 55% of the studies. The activities related to the CNS (antidepressant, neuroprotective, cholinergic, etc.), anti-inflammatory and analgesic effects accounted for almost 25% of the studies (Figure 4).

**Antitumor activity**

The composition of the human diet can influence the risk of cancer and its components can exert positive or negative influences [66]. Chemoprevention is the long-term pharmacological control on the risk of cancer. On this matter, several plants, together with their compounds, have been investigated for their antitumor potential [66,67]. About 70% of the drugs used in cancer treatment derive from natural products [68].

As previously described, rosemary is known to exert antioxidant activity thus inhibiting genotoxicity, and protecting from carcinogens or toxic agents [69]. However, the pronounced side effects of the therapeutic methods largely prevent its effectiveness, increasing the demand for new approaches in cancer treatment and prevention [70].

Polyphenols are compounds capable of modulating cell growth and differentiation and thus interfere with tumor development and progression [71]. Since rosemary is rich in phenolic compounds, many studies have been targeted for antitumor activity (about 20%) (Figure 4) [62,72–75].

Carnosic acid and carnosol are diterpenes that represent about 5% of *R. officinalis* dried leaves weight, and these compounds have greater antitumor relevance (35 in 49 studies use these compounds). There has been a large increase in the number of studies regarding the antitumor activity of carnosic acid, carnosol, rosmarinic acid, ursolic
Table 3. Evolution of studies with compounds over the years according to all reviewed articles.

| Year | Carnosol | CA | RA | UA | EO | Others | Total |
|------|----------|----|----|----|----|--------|-------|
| 1990 | 0        | 0  | 0  | 0  | 0  | 0      | 0     |
| 1991 | 0        | 0  | 0  | 0  | 1  | 0      | 1     |
| 1992 | 1        | 2  | 0  | 0  | 0  | 0      | 3     |
| 1993 | 0        | 0  | 0  | 0  | 2  | 0      | 2     |
| 1994 | 2        | 0  | 0  | 2  | 0  | 0      | 4     |
| 1995 | 2        | 1  | 0  | 0  | 0  | 0      | 3     |
| 1996 | 2        | 0  | 0  | 0  | 0  | 0      | 2     |
| 1997 | 0        | 0  | 0  | 0  | 0  | 0      | 0     |
| 1998 | 0        | 0  | 0  | 0  | 0  | 0      | 0     |
| 1999 | 0        | 0  | 0  | 0  | 4  | 0      | 4     |
| 2000 | 0        | 0  | 0  | 0  | 1  | 0      | 1     |
| 2001 | 2        | 2  | 0  | 0  | 1  | 2      | 7     |
| 2002 | 2        | 4  | 2  | 3  | 0  | 0      | 11    |
| 2003 | 2        | 3  | 1  | 0  | 1  | 1      | 8     |
| 2004 | 1        | 3  | 0  | 0  | 2  | 1      | 7     |
| 2005 | 2        | 0  | 0  | 0  | 0  | 0      | 2     |
| 2006 | 3        | 5  | 2  | 0  | 3  | 0      | 13    |
| 2007 | 1        | 4  | 0  | 1  | 8  | 2      | 16    |
| 2008 | 1        | 5  | 1  | 0  | 4  | 0      | 11    |
| 2009 | 0        | 2  | 2  | 1  | 1  | 1      | 7     |
| 2010 | 7        | 10 | 5  | 2  | 12 | 3      | 39    |
| 2011 | 3        | 9  | 2  | 2  | 11 | 2      | 29    |
| 2012 | 5        | 10 | 5  | 3  | 8  | 4      | 35    |
| 2013 | 8        | 10 | 11 | 1  | 5  | 7      | 42    |
| 2014 | 2        | 14 | 1  | 1  | 10 | 0      | 28    |

CA: Carnosic acid; EO: Essential oil; RA: Rosmarinic acid; UA: Ursolic acid.

CA: Carnosic acid; EO: Essential oil; RA: Rosmarinic acid; UA: Ursolic acid.

Figure 4. Ratio on the number of studies (%) to the studied biological activities on *R. officinalis* according to the literature.

acid over the past 5 years (Table 3). Breast cancers, melanoma, colon cancer, liver carcinoma and leukemia have been the most studied. In fact, there has been several *in vitro* studies regarding cytotoxicity of carnosol and carnosic acid to human cancer cells (HepG2, COLO 205 and HL-60), breast cancer cells and colon cancer cells [73,76]. These studies reported a decrease of cell viability using carnosic acid in a dose-dependent manner, including resistant tumor cells, suggesting this compound as a complementary antitumoral approach [77].
From *in vivo* experiments, carnosic acid and its ester derivatives were found to be effective in preventing gastric lesions in HCl/EtOH-induced gastric lesions model in mice [78]. Also, treatment with rosemary extract of 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumorigenesis in rats, suggested a chemopreventative action for experimental mammary tumorigenesis [79].

More detailed information concerning *in vitro* and *in vivo* experimental studies is displayed in the tables in Supplementary material.

**Antioxidant activity**

The natural antioxidants from plants are becoming increasingly important, not only in the nutritional area (food preservation and stability) but also in preventive medicine [80]. The Lamiaceae family has been a focus of the research on antioxidant compounds due to its high polyphenol content [81]. Likewise *R. officinalis* leaves are commonly used as a condiment for flavoring food, and as a source of antioxidant compounds employed in food conservation [82].

Antioxidants play a major role in the prevention and treatment of diseases associated with oxidative damage, including cancer, cardiovascular and neurodegenerative diseases [80,83–86]. Reactive oxygen species, including hydrogen peroxide and free radicals, such as superoxide anion (O$_2^-$) and hydroxyl radical (HO$^-$), are inevitably produced in living organisms resulting from metabolic processes or from external sources [81]. Continued exposure to free radicals in biological systems may cause functional and structural damage, aging and cell death [85].

Several *in vitro* studies were reviewed regarding the antioxidant activity of the main isolated compounds from rosemary, namely, carnosol, carnosic acid, rosmanol, rosmarinic acid, oleanolic acid and ursolic acid. Using the 2,2-diphenyl-1-picrylhydrazyl method, these bioactive compounds and the essential oil were validated for their antioxidant activity [86–88]. Also, using the thiobarbituric acid, superoxide anion and lipid free radicals scavenging activity assays and Rancimat methods (determination of oxidative stability of fat), the bioactive compounds carnosol, rosmanol and epirosmanol have been reported to inhibit lipid peroxidation through the lipid free radical scavenging mechanism [58,89–90]. These studies have shown the antioxidant potential of rosemary phytochemicals, whose properties are closely related to other biological activities, such as cytoprotective and anticancer, primarily due to their ability to neutralize reactive oxygen species.

Considering *in vivo* studies, there were only three different studies found until 2014 for the validation of *in vitro* experimental results, using the essential oil and carnosic acid. These studies were performed using Wistar rats, and evaluated the catalase, glutathione peroxidase, superoxide dismutase and nitric oxide synthase activities, as well as lipid peroxidation and reactive oxygen species, in brain and heart tissues after diet supplementation with rosemary essential oil. This resulted in the decrease of oxidative stress, since dietary rosemary has the potential to quench free radicals, inhibit lipid peroxidation and improve the antioxidant status in rat tissues [55,81,91].

More detailed information concerning *in vitro* and *in vivo* experimental studies is displayed in the tables in Supplementary material.

**Anti-infectious activity**

Most plants produce antimicrobial secondary metabolites, either from its normal course of growth and development, or in response to stress or pathogen attack. The use of essential oils represents a new way to reduce the proliferation of microorganisms [92]. *Rosmarinus officinalis* L. is widely used today as a food preservative and known for its powerful antibacterial activity [93].

The increasing use of antibiotics in medicine, agriculture and livestock has largely contributed to the increase of multiple drug resistant microorganisms [94]. Antimicrobial resistance is a global public health concern, and researchers have been increasingly engaging in this area in demand for new effective antimicrobial bioactives [94,95].

Besides the antibacterial properties, essential oils also have insecticidal, antiparasitic and antifungal activities, which are important for the control of human diseases of microbial origin [96].

Since the 1990s until 2014, the essential oil of rosemary has demonstrated the highest antimicrobial activity, with 65% of anti-infectious activity studies. The antimicrobial activity of the essential oil was superior, when compared with the single compounds α-pinene and α-pinene [97].

Experimental *in vitro* studies, concerning MICs, minimal bactericidal concentration and time-kill dynamic processes, have reported that there is a possible synergistic effect between the antimicrobial compounds in essential oil [96,98]. These studies were performed testing carnosic acid, carnosol, rosmarinic acid, oleanolic acid, ursolic acid and essential oil, against Gram-positive bacteria (*Staphylococcus epidermidis, Staphylococcus aureus and Bacillus subtilis*), three Gram-negative bacteria (*Proteus vulgaris, Pseudomonas aeruginosa and Escherichia coli*) and two fungi...
(Candida albicans and Aspergillus niger). All reported pronounced antibacterial and antifungal activity (20; 227; 87; 136; 97; 93). It was also found that carnosic acid showed antiviral activity against human respiratory syncytial virus [99].

More detailed information concerning in vitro experimental studies is displayed in the tables in Supplementary material.

**Anti-inflammatory & analgesic activities**

Plants are a good source of anti-inflammatory agents and the continuous search for new compounds, especially from plants with historically documented pharmacological effects, represents a huge pharmaceutical potential [82].

Controlling the release of mediators in the inflammatory process is the main objective of anti-inflammatory drugs [100]. Pain and inflammation are related to wound healing and production of free radicals which could extend the inflammation process [101]. Thus, the inflammatory response and the oxidative damage are two main factors that induce cardiovascular and neurodegenerative diseases; however, polyphenols from some plants are able to reduce these problems [102].

In folk medicine, rosemary is known for its therapeutic properties against abdominal pain and for the treatment of respiratory inflammatory diseases, such as bronchial asthma [103].

Some experimental studies have reported the anti-inflammatory and analgesic activities of the essential oil and biologically active terpenes such as carnosic acid, carnosol, ursolic acid and betulinic acid, as well as rosmarinic acid, rosmanol and oleanolic acid [82]. In fact, it has been reported that they have antinociceptive activity, and that each individual triterpene showed a similar potency to that observed with ketorolac, a nonsteroidal anti-inflammatory drug [82,104].

Regarding in vitro studies, the anti-inflammatory and analgesic studies were based on the evaluation of the expression of inflammatory cytokines (IL-1β, IL-6, TNF-α, etc.), COX-1/COX-2, iNOS and evaluation of nitric oxide production in RAW 264.7 macrophages cells [72,86,105–106]. Also, studies concerning the antitherosclerotic effects of rosemary have been developed, through the migration and matrix metalloproteinase activation of vascular smooth muscle cells. These studies reported that carnosic acid has an ability to suppress matrix metalloproteinase-9 expression through downregulation of NF-κB and therefore decrease the smooth muscle cells migration [107,108].

It is apparent that the anti-inflammatory and analgesic activities have been the most studied, and there is an attempt to explain these properties with several compounds of R. officinalis, with carnosol the most investigated (Figure 4). These in vitro studies have shown a potential application for the prevention of inflammatory diseases [106].

At preclinical stages, the essential oil of rosemary has been used topically for muscular and rheumatic pains, evaluated using carrageenan-induced pleurisy and carrageenan-induced paw edema tests in rats. These studies suggested that the essential oil could remarkably decrease the induced edema in 1–4 h and significantly reduce the volume of pleural exudate, being both anti-inflammatory and antinociceptive [60,109]. Also, new lead compounds obtained by rosmarinic acid derivatization have been tested for these activities. Particularly, the acetyl derivative can reduce the induced paw edema as well as the paw licks, suggesting a potential application of this compound as anti-inflammatory and antinociceptive agent [109]. Regarding clinical trials in this topic, there have been several studies since 2005. Lukaczer et al. reported the efficacy of ‘Meta050’ (a combination of reduced iso-alpha-acids from hops, rosemary extract and oleanolic acid), in patients with rheumatic disease. Patients with pain caused by osteoarthritis, rheumatoid arthritis and fibromyalgia were given 440 mg of ‘Meta050’, which doubled after 4 weeks in the majority of patients. This work reports a significant decrease in pain in arthritis subjects by 40–50%, but not for fibromyalgia subject scores [110].

The ex vivo clinical study performed by Minich et al. on pain relief used a combination similar to ‘Meta050’, but is here presented as NG440. The goal was to examine the clinical safety and efficacy of NG440. The report suggested that NG440 is safe for human consumption and that animal toxicity revealed no adverse effects, at daily dosages ≤250 mg/kg. According to these results, NG440 may serve as an alternative where specific COX-2 inhibitors have been traditionally used [111].

Other work performed by Rosenbaum et al. [105] reported the use of triterpenes, ursolic acid, oleanolic acid and micromeric acid as dietary supplements for osteoarthritis and rheumatoid arthritis. These compounds (obtained from different extracts of rosemary leaf), were able to decrease topical anti-inflammatory activity, which was tested using the croton oil ear test in mice.
However, it is not clear if any of these supplements can be effectively and safely recommended to reduce nonsteroidal anti-inflammatory drug or steroid usage, thus, more research is required. More information is displayed in the tables in Supplementary material.

CNS & endocrine system activities
Diabetes mellitus is one of the most prevalent metabolic disorders in the world. Insulin and oral hypoglycemic agents are used to treat diabetes; however, these drugs do not cure the disease and have significant adverse effects [112]. Rosemary has been shown to decrease blood glucose in several in vivo studies [113]. Some in vitro and in vivo studies have reported an inhibition of gastric lipase in the stomach of Zucker rats, after treatment with high contents of carnosic acid, which resulted in an improve of the triglycerides profiles [65,113]. Therefore, carnosic acid together with carnosol, proved to be the most relevant compounds on glycemic control. Furthermore, there has been a growing trend of studies for new neuroprotective drugs from natural sources, which raises a new therapeutic hope [114]. Diseases of the CNS (depression, Parkinson, Alzheimer, etc.) are incurable chronic conditions, and presumably that is why there has been an increasing number of studies in R. officinalis over recent years, in an attempt to find new solutions. Regarding depression there are several studies reporting a decreasing immobility time and regulation of several neurotransmitters (dopamine, norepinephrine, serotonin and acetylcholine) and gene expression in mice brain like TH, PC and MAPK phosphatase (MKP-1) [115,116]. These studies contribute to the understanding of molecular mechanism behind the antidepressant effect of R. officinalis and its major active compounds. Rosmarinic acid, however, seems to have potential against neurodegenerative diseases. It was found that this compound had cholinergic and neuroprotective effects and inhibited acetylcholinesterase [114,117].

Regarding clinical trials, in 2010, Pengelly et al. performed a randomized, placebo-controlled, double-blinded, repeated-measures crossover study to investigate possible acute effects of dried rosemary leaf powder on cognitive performance. This work reported significant speed of memory – a potentially useful predictor of cognitive function during aging, using rosemary powder at the dose normally used at culinary consumption. This work expands the value of future studies on effects of low doses of rosemary on memory and cognition [118]. More detailed information concerning in vitro and in vivo experimental studies is displayed in the tables in Supplementary material.

Discussion
A total of 286 articles were obtained from the searched databases, comprising 232 based on biological activities (knowing that some publications report more than one activity) and 275 based on biological activity regarding isolated compounds. Publications were excluded based on restricted access to abstract, research area on nutrition (food supplements or stability) and irrelevant or unreliable results on biological activities. This review allows us to connect the biological activities of R. officinalis isolated compounds under search with essential oils and/or extracts.

From this review, it can be concluded that R. officinalis has a promising future especially in the treatment and prevention of various diseases, such as cancers, infectious diseases and CNS disorders. Interestingly, using the database from ClinicalTrials.gov with the same keywords under study, we found two clinical trials for rosmarinic acid and oleanolic acid, three studies for ursolic acid and none for carnosic acid or carnosol. These studies concern the topics of osteoarthritis of the knee, nasal polyps, GI tract, cardiovascular diseases, metabolic syndrome X, sarcopenia and benign prostatic hyperplasia. Thus, it is imperative to improve clinical studies of this medicinal plant, and learn from the traditional health practitioners that bear the knowledge of many generations of trial and error. The worldwide interest in the use of rosemary has been growing with its beneficial effects being rediscovered for the possible development of new drugs. Therefore, the need for new therapeutic agents with specific targets and less adverse side effects, supports the need to extend both the clinical and preclinical studies on R. officinalis plants.

Conclusion
In recent years, much effort has been devoted to the development of PBMs [22], proposing them as natural drugs in many pathological conditions including anti-inflammatory, analgesic, antioxidant, antitumor, anti-infectious, CNS and endocrine system activities.

Phytotherapy is a major contributor to the discovery of new, safer and effective PBMs, as well as new drugs, knowing that what pharmaceutical chemistry has sought desperately, nature has in large quantities [12].
Based on the development of high-accuracy analytical methods and the advances of molecular biology and genetics, it is now possible to isolate plant compounds that exist in extremely small quantities [31]. With these improvements, it is now possible to study their chemical structure and therapeutic potential, and thus, modify the molecule for producing new, more selective therapeutic agents [12,31,119].

This work performed an updated review on *R. officinalis* L., allowing us to emphasize the current state of the art, on studies and investigations, pointing out the awareness of the pharmacological activities related to the constituents of this plant. Since 1990s, there has been an increasing therapeutic interest in rosemary, from both *in vitro* and *in vivo* studies on several biological activities, such as antioxidant, anti-inflammatory, analgesic, etc., previously described in ethnobotanical studies.

From the reviewed literature, it can be concluded that the most important constituents of *R. officinalis* L., which are pharmacologically active and the main target of scientific studies, are carnosic acid, carnosol, rosmarinic acid and the essential oil. Thus, these natural drugs can be proposed for preclinical and clinical studies in different diseases and pathological conditions.

*R. officinalis* has a promising future in the medical field, especially in the treatment and prevention of various cancers, infectious diseases and increasingly emerging diseases such as depression, Alzheimer’s and Parkinson’s diseases. In fact, there are 80 clinical studies on *R. officinalis*, from which 32 are still open studies.

These studies regarding herbal remedies should be taken into more consideration since the safety and efficacy of many herbal medicines are still problematic, with inadequate or inconsistent methods. Considering this, more reliable trials are needed in the future to evaluate the *R. officinalis* active phytocompounds safety and efficacy, in treating different pathological conditions.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Open access

This work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Author’s contributions

Literature research and writing have been done by D Ladeiras, C Garcia, CP Reis and JM Andrade. Actualization has been done by JM Andrade. English vocabulary as well as phrase structure revision of the whole document have been done by C Faustino. P Rijo was the supervisor of all work.

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.future-science.com/doi/suppl/10.4155/fsoa-2017-0124

References

1. Batanouny KH, Aboutabl E, Shabana MC, Soliman F. *Wild Medicinal Plants in Egypt: An Inventory to Support Conservation and Sustainable Use*. Academy of Scientific Research & Technology, Cairo, Egypt (1999).
2. Cragg GM, Newman DJ. Natural products: a continuing source of novel drug leads. *Biochim. Biophys. Acta* 1830(6), 3670–3695 (2013).
3. Mukherjee PK, N SK, Heinrich M. Plant Made Pharmaceuticals (PMPs) – development of natural health products from bio-diversity. *Indian J. Pharm. Educ. Res.* 42(2), 113–121 (2008).
4. Jardak M, Elloumi-Mseddi J, Aifa S, Mnif S. Chemical composition, anti-biofilm activity and potential cytotoxic effect on cancer cells of *Rosmarinus officinalis* L. essential oil from Tunisia. *Lipids Health Dis.* 16(1), 190 (2017).
5. Habtemariam S. The therapeutic potential of rosemary (*Rosmarinus officinalis*) diterpenes for Alzheimer’s disease. *Evid. Based Complement. Alternat. Med.* 2016, 2680409 (2016).
6. Mendonça-Filho RR. Bioactive phytocompounds: new approaches in the phytosciences. In: *Modern Phytopharmacy: Turning Medicinal Plants into Drugs*. Ahmad I, Aqil F, Owais M (Eds). John Wiley & Sons, Weinheim, Germany, 1–24 (2006).
7. Swain T. *Plants in the Development of Modern Medicine*. Harvard University Press. Cambridge, Massachusetts (1972).
8. Cragg GM, Newman DJ. Drugs from nature: past achievements, future prospects. In: *Ethnomedicine and Drug Discovery*. Iwu M, Wootton J (Eds). Elsevier, New York, USA, 23–37 (2002).

9. Heinrich M, Barnes J, Gibbons S, Williamson E. *Fundamentals of Pharmacognosy and Phytotherapy* (2nd Edition). Elsevier Health Sciences, Edinburgh, UK.

10. Rotblatt M. Herbal medicine: expanded commission E monographs. *Ann. Intern. Med.* 133(6), 487 (2000).

11. Food Standards Agency. Current EU approved additives and their E Numbers. Food Standards Agency. (2016). www.food.gov.uk/science/additives/enumberlist

12. Mohamed I, Shuid A, Borhanuddin B, Fozii N. The application of phytomedicine in modern drug development. *Internet J. Herb. Plant Med.* 1(2), 14–27 (2012).

13. Cordell GA, Colvard MD. Some thoughts on the future of ethnopharmacology. *J. Ethnopharmacol.* 100(1–2), 5–14 (2005).

14. Calixto JB. Twenty-five years of research on medicinal plants in Latin America: a personal view. *J. Ethnopharmacol.* 100(1–2), 131–134 (2005).

15. Rates SMK. Plants as source of drugs. *Toxicol.* 39(5), 603–613 (2001).

16. Salim AA, Chin Y-W, Kinghorn AD. Drug discovery from plants. In: *Bioactive Molecules and Medicinal Plants*. Ramawat KG, Merillon JM (Eds). Springer, Berlin and Heidelberg, Germany, 1–24 (2008).

17. Bandaranayake WM. Quality control, screening, toxicity, and regulation of herbal drugs. In: *Modern Phytochemistry: Turning Medicinal Plants into Drugs*. Ahmad I, Agil F, Owais M (Eds). John Wiley & Sons, Weinheim, Germany, 25–57 (2006).

18. Rout SP, Choudary KA, Kar DM, Das L, Jain A. Plants in traditional medicinal system – future source of new drugs. *Int. J. Pharm. Pharm. Sci.* 1(1), 1–23 (2009).

19. Samuelsson G, Bohlin L. *Drugs of Natural Origin: A Treatise of Pharmacognosy* (6th Edition). Swedish Pharmaceutical Press, Stockholm, Sweden (2001).

20. Kinne-Saffran E, Kinne RKH. Vitalism and synthesis of urea. *Am. J. Nephrol.* 19(2), 290–294 (1999).

21. Balunas MJ, Kinghorn AD. Drug discovery from medicinal plants. *Life Sci.* 78(5), 431–441 (2005).

22. Keservani RK, Sharma AK, Kesharwani RK, IGI Global. Phytopharmaceuticals and its applications in therapy. In: *Recent Advances in Drug Delivery Technology*. IGI Global, Delhi, India, 202–229 (2017).

23. Iwu MM. Therapeutic agents from ethnomedicine. In: *Ethnomedicine and Drug Discovery*. Iwu M, Wootton J (Eds). Elsevier, New York, USA, 1–22 (2002).

24. Hamburger M, Hostettmann K. Bioactivity in plants: the link between phytochemistry and medicine. *Phytochemistry* 30(12), 3864–3874 (1991).

25. Oyebode O, Kandala N-B, Chilton PJ, Lilford RJ. Use of traditional medicine in middle-income countries: a WHO-SAGE study. *Health Policy Plan.* 31(8), 984–991 (2016).

26. Robbers JE, Speedie MK, Tyler VE. *Pharmacognosy and Pharmacobiotechnology*. Williams & Wilkins, MD, USA.

27. Krogsgaard-Larsen P, Christensen SB, Kofod H. The role of Medicinal plants in drug development. In: *Natural Products and Drug Development*. Munksgaard, Copenhagen, Denmark, 34–45 (1994).

28. Raskin I, Ribnicky DM, Komarnytsky S *et al.* Plants and human health in the twenty-first century. *Trends Biotechnol.* 20(12), 522–531 (2002).

29. Fabricant DS, Farnsworth NR. The value of plants used in traditional medicine for drug discovery. *Environ. Health Perspect.* 109(Suppl. 1), 69–75 (2001).

30. Katiyar C, Gupta A, Kanjilal S, Katiyar S. Drug discovery from plant sources: an integrated approach. *Ayu* 33(1), 10–19 (2012).

31. Badal McCreath S, Delgoda R. Metabolomics approach in pharmacognosy. In: *Pharmacognosy: Fundamentals, Applications and Strategies*. Badal McCreath S, Delgoda R (Eds). Academic Press, London, UK, 597–630 (2017).

32. Ahmad I, Agil F, Ahmad F, Owais M. Herbal medicines: prospects and constraints. In: *Modern Phytochemistry: Turning Medicinal Plants into Drugs*. Ahmad I, Agil F, Owais M (Eds.) John Wiley & Sons, Weinheim, Germany, 59–77 (2006).

33. Kamboj A. Analytical evaluation of herbal drugs. In: *Drug Discovery Research in Pharmacognosy*. Vallisuta O (Ed.). InTech, Rijeka, Croatia, 23–60 (2012).

34. Goldman P. Herbal medicines today and the roots of modern pharmacology. *Ann. Intern. Med.* 135(8 Pt 1), 594–600 (2001).

35. Naghibi F, Mosaddegh M, Motamed SM, Ghorbani A. Labiatae family in folk medicine in Iran: from ethnobotany to pharmacology. *Iran. J. Pharm. Res.* 63–79 (2005).

36. Raja RR. Medicinally potential plants of Labiatae (Lamiaceae) family: an overview. *Res. J. Med. Plant.* 6(3), 203–213 (2012).

37. Wagstaff SJ, Hickerson L, Spangler R, Reeves PA, Olmstead RG. Phylogeny in Labiatae sl, inferred from cpDNA sequences. *Plant Syst. Evol.* 209(3–4), 265–274 (1998).
38. Begum A, Sandhya S, Shaffath Ali S, Vinod KR, Reddy S, Banji D. An in-depth review on the medicinal flora Rosmarinus officinalis (Lamiaceae). Acta Sci. Pol. Technol. Aliment. 12(1), 61–73 (2013).

39. Al-Sereiti MR, Abu-Amer KM, Sen P. Pharmacology of rosemary (Rosmarinus officinalis Linn.) and its therapeutic potentials. Indian J. Exp. Biol. 37(2), 124–130 (1999).

40. WHO. WHO monographs on selected medicinal plants. World Health Organization, Geneva. http://apps.who.int/medicinedocs/en/d/Jf2200e/

41. Comissão Permanente da Farmacopeia Portuguesa. Farmacopeia Portuguesa (7th Edition). Ministério da Saúde, Lisbon, Portugal (2003).

42. Badal McCreath S, Delgoda R. Pharmacognosy: fundamentals, applications and strategies. Academic Press, London, UK (2016).

43. Handa SS. Extraction technologies for medicinal and aromatic plants. International Centre for Science and High Technology. www.unido.org/sites/default/files/2009-10/Extraction_technologies_for_medicinal_and_aromatic_plants_0.pdf

44. Gupta A, Naranival M, Kothari V. Modern extraction methods for preparation of bioactive plant extracts. Int. J. Appl. Nat. Sci. 1(1), 8–26 (2012).

45. Azmir J, Zaidul ISM, Rahman MM et al. Techniques for extraction of bioactive compounds from plant materials: a review. J. Food Eng. 117(4), 426–436 (2013).

46. Lovkova MY, Buzuk GN, Sokolova SM, Kliment’eva NI. Chemical features of medicinal plants (review). Appl. Biochem. Microbiol. 37(3), 229–237 (2001).

47. Faixová Z, Faix S. Biological effects of rosemary (Rosmarinus officinalis L.) essential oil (a review). Folia Vet. 52, 135–139 (2008).

48. Ulbricht C, Abrams TR, Brigham A et al. An evidence-based systematic review of rosemary (Rosmarinus officinalis) by the Natural Standard Research Collaboration. J. Diet. Suppl. 7(4), 351–413 (2010).

49. Aumeeruddy-Elalfi Z, Gurib-Fakim A, Mahomoodally MF. Chemical composition, antimicrobial and antibiotic potentiating activity of essential oils from 10 tropical medicinal plants from Mauritius. J. Ethnopharmacol. 117(4), 426–436 (2013).

50. Aumeeruddy-Elalfi Z, Gurib-Fakim A, Mahomoodally F. Antimicrobial, antibiotic potentiating activity and phytochemical profile of essential oils from exotic and endemic medicinal plants of Mauritius. Ind. Crops Prod. 71, 197–204 (2015).

51. Bozin B, Mimica-Dukic N, Samojlik I, Jovin E. Antimicrobial and antioxidant properties of rosemary and sage (Salvia officinalis L., Lamiaceae) essential oils. J. Agric. Food Chem. 55(19), 7879–7885 (2007).

52. Evans WC. Trease and Evans’ Pharmacognosy (16th Edition). Elsevier Health Sciences, Edinburgh, UK (2009).

53. Bachmayer HW. Herbal Drugs and Phytopharmaceuticals (3rd Edition). Medpharm, Stuttgart, Germany (2004).

54. Doughari JH. Phytochemicals: extraction methods, basic structures and mode of action as potential chemotherapeutic agents. In: Phytochemicals – A Global Perspective of Their Role in Nutrition and Health. Rao V (Ed.). InTech, Rijeka, Croatia, 1–32 (2012).

55. Posadas SJ, Caz V, Largo C et al. Protective effect of supercritical fluid rosemary extract, Rosmarinus officinalis, on antioxidants of major organs of aged rats. Exp. Gerontol. 44(6–7), 383–389 (2009).

56. Zhang Y, Adelakun TA, Qu L et al. New terpenoid glycosides obtained from Rosmarinus officinalis L. aerial parts. Fitoterapia. 99, 78–85 (2014).

57. Calvo MI, Akerreta S, Cavero RY. Pharmaceutical ethnobotany in the Riverside of Navarra (Iberian Peninsula). J. Ethnopharmacol. 135(1), 22–33 (2011).

58. Bakirel T, Bakirel U, Keles¸ OU, Ulgen SG, Yardibi H. New terpenoid glycosides obtained from Rosmarinus officinalis L. Anti-inflammatory and antinociceptive effects of Rosmarinus officinalis L. polyphenols on membrane phospholipid order. J. Agric. Food Chem. 58(1), 161–170 (2010).

59. Pérez-Fons L, Garzón MT, Micol V. Relationship between the antioxidant capacity and effect of rosemary (Rosmarinus officinalis L.) polyphenols on membrane phospholipid order. J. Agric. Food Chem. 58(1), 161–170 (2010).

60. Romo Vaquerò M, Yáñez-Gascón M-J, García Villalba R et al. Inhibition of gastric lipase as a mechanism for body weight and plasma lipids reduction in Zucker rats fed a rosemary extract rich in carnosic acid. PLoS ONE 7(6), e39773 (2012).

61. Visanji JM, Thompson DG, Padfield PJ. Induction of G2/M phase cell cycle arrest by carnosol and carnosic acid is associated with alteration of cyclin A and cyclin B1 levels. Cancer Lett. 237(1), 130–136 (2006).
67. Sancheti G, Goyal P. Modulatory influence of Rosmarinus officinalis on DMBA-induced mouse skin tumorigenesis. Asian Pacific J. Cancer Prev. 7(2), 331–335 (2006).

68. Prasad S, Yadav VR, Kannappan R, Aggarwal BB. Ursolic acid, a pentacyclin triterpene, potentiates TRAIL-induced apoptosis through p53-independent up-regulation of death receptors: evidence for the role of reactive oxygen species and JNK. J. Biol. Chem. 286(7), 5546–5557 (2011).

69. González-Vallinas M, Molina S, Vicente G et al. Expression of microRNA-15b and the glycosyltransferase GCNT3 correlates with antitumor efficacy of Rosmarinus diterpenes in colon and pancreatic cancer. PLoS ONE 9(6), e98556 (2014).

70. Xiang Q, Ma Y, Dong J, Shen R. Carnosic acid induces apoptosis associated with mitochondrial dysfunction and Akt inactivation in HepG2 cells. Int. J. Food Sci. Nutr. 74(6), 1–9 (2014).

71. Kar S, Palit S, Ball WB, Das PK. Carnosic acid modulates Akt/IKK/NF-kB signaling by PP2A and induces intrinsic and extrinsic pathway mediated apoptosis in human prostate carcinoma PC-3 cells. Apoptosis 17(7), 735–747 (2012).

72. Huang MT, Ho CT, Wang ZY et al. Inhibition of skin tumorigenesis by rosemary and its constituents carnosol and ursolic acid. Cancer Res. 54(3), 701–708 (1994).

73. Dörrie J, Sapala K, Zunino SJ. Carnosol-induced apoptosis and downregulation of Bcl-2 in B-lineage leukemia cells. Cancer Lett. 170(1), 33–39 (2001).

74. Tsai C, Lin C, Wang Y. Carnosic acid induces the NAD(P)H: quinone oxidoreductase 1 expression in rat clone 9 cells through the p38/nuclear factor erythroid-2 related factor 2 pathway. J. Nutr. 141(12), 2119–2125 (2011).

75. Barni MV, Carlini MJ, Caffereta EG, Puricelli L, Moreno S. Carnosic acid inhibits the proliferation and migration capacity of human colorectal cancer cells. Oncol. Rep. 27(4), 1041–1048 (2012).

76. Bai N, He K, Roller M et al. Flavonoids and phenolic compounds from Rosmarinus officinalis. J. Agric. Food Chem. 58(9), 5363–5367 (2010).

77. González-Vallinas M, Molina S, Vicente G et al. Antitumor effect of 5-fluorouracil is enhanced by rosemary extract in both drug sensitive and resistant colon cancer cells. Pharmacol. Res. 72, 61–68 (2013).

78. Theodoroulou C, Perrino MW, Rodríguez JA, Schmeda-Hirschmann G. Gastroprotective effect and cytotoxicity of carnosic acid derivatives. Planta Med. 77(9), 882–887 (2011).

79. Singletry K, MacDonald C, Wallig M. Inhibition by rosemary and carnosol of 7,12-dimethylbenz[a]anthracene (DMBA)-induced rat mammary tumorigenesis and in vivo DMBA-DNA adduct formation. Cancer Lett. 104(1), 43–48 (1996).

80. Lee K-G, Shibusawa K. Determination of antioxidant potential of volatile extracts isolated from various herbs and spices. J. Agric. Food Chem. 50(17), 4947–4952 (2002).

81. Botsoglou N, Taitzoglou I, Zervos I, Botsoglou E, Tsantarliotou M, Chatzopoulou PS. Potential of long-term dietary administration of rosemary in improving the antioxidant status of rat tissues following carbon tetrachloride intoxication. Food Chem. Toxicol. 48(3), 944–950 (2010).

82. Benincà JP, Dalmarco JB, Pizzolatti MG, Fröde TS. Analysis of the anti-inflammatory properties of Rosmarinus officinalis L. in mice. Food Chem. 124(2), 468–475 (2011).

83. Leal PF, Braga MEM, Sato DN, Carvalho JE, Marques MOM, Meireles MAA. Functional properties of spice extracts obtained via supercritical fluid extraction. J. Agric. Food Chem. 51(9), 2520–2525 (2003).

84. Ahern SA, Kerry JP, O’Brien NM. Effects of plant extracts on antioxidant status and oxidant-induced stress in Caco-2 cells. Br. J. Nutr. 97(2), 321–328 (2007).

85. Guijarro ME, García AF, Africa de Madariaga M, Sagrista ML, Casadó FJ, Mora A. Interaction of tocopherols and phenolic compounds with membrane lipid components: evaluation of their antioxidant activity in a liposomal model system. Life Sci. 72(21), 2337–2360 (2003).

86. Lo A, Liang Y, Lin-Shiau S-Y, Ho C, Lin J. Carnosol, an antioxidant in rosemary, suppresses inducible nitric oxide synthase through down-regulating nuclear factor-kappaB in mouse macrophages. Carcinogenesis 23(6), 983–991 (2002).

87. Klancnik A, Guzej B, Kolar MH, Abramovic H, Mozina SS. In vitro antimicrobial and antioxidant activity of commercial rosemary extract formulations. J. Food Prot. 72(8), 1744–1752 (2009).

88. Beretta G, Artali R, Facino RM, Gelmini F. An analytical and theoretical approach for the profiling of the antioxidant activity of essential oils: the case of Rosmarinus officinalis L. J. Pharm. Biomed. Anal. 55(5), 1255–1264 (2011).

89. Zeng HH, Tu PF, Zhou K, Wang H, Wang BH, Lu JF. Antioxidant properties of phenolic diterpenes from Rosmarinus officinalis. Acta Pharmacol. Sin. 22(12), 1094–1098 (2001).

90. del Baño MJ, Lorente J, Castillo J et al. Phenolic diterpenes, flavones, and rosmarinic acid distribution during the development of leaves, flowers, stems, and roots of Rosmarinus officinalis. Antioxidant activity. J. Agric. Food Chem. 51(15), 4247–4253 (2003).

91. Rašković A, Milanović I, Pavlović N, Cevušić T, Vukmirović S, Mitkov M. Antioxidant activity of rosemary (Rosmarinus officinalis L.) essential oil and its hepatoprotective potential. BMC Complement. Altern. Med. 14, 225 (2014).
92. Kačániová M, Vuković N, Horská E et al. Antibacterial activity against Clostridium genus and antiradical activity of the essential oils from different origin. *J. Environ. Sci. Health. B* 49(7), 505–512 (2014).

93. Wang W, Li N, Luo M, Zu Y, Effert M. Antibacterial activity and anticancer activity of *Rosmarinus officinalis* L. essential oil compared to that of its main components. *Molecules* 17(3), 2704–2713 (2012).

94. Qabaha K. Antimicrobial and free radical scavenging activities of five palestinian medicinal plants. *African J. Tradit. Complement. Altern. Med.* 10(4), 101–108 (2013).

95. Petrolini FVB, Lucarini R, de Souza MGM, Pires RH, Canha WR, Martins CHG. Evaluation of the antibacterial potential of *Petromelum erizum* and *Rosmarinus officinalis* against bacteria that cause urinary tract infections. *Brazilian J. Microbiol.* 44(3), 829–834 (2013).

96. Luqman S, Dwivedi GR, Darokar MP, Kalra A, Khanuja SPS. Potential of rosemary oil to be used in drug-resistant infections. *Altern. Ther. Health Med.* 13(5), 54–59 (2007).

97. Jiang Y, Wu N, Fu Y J et al. Chemical composition and antimicrobial activity of the essential oil of rosemary. *Environ. Toxicol. Pharmacol.* 32(1), 63–68 (2011).

98. Swamy MK, Akhtar MS, Sinniah UR. Antimicrobial Properties of Plant Essential Oils against Human Pathogens and Their Mode of Action: An Updated Review. *Evid Based Complement Alternat Med.* 2016 (ID 3012462), 1-21 (2016).

99. Shin H-B, Choi M-S, Ryu B et al. Antiviral activity of carnosic acid against respiratory syncytial virus. *Virology J.* 10(1), 303 (2013).

100. da Rosa JS, Facchin BM, Bastos J et al. Systemic administration of *Rosmarinus officinalis* attenuates the inflammatory response induced by carrageenan in the mouse model of pleurisy. *Plantas Med.* 79(17), 1605–1614 (2013).

101. Backhouse N, Rosales L, Apablaza C et al. Analgesic, anti-inflammatory and antioxidant properties of *Buddleja globosa*, *Buddlejaceae*. *J. Ethnopharmacol.* 116(2), 263–269 (2008).

102. Peng C-H, Su J-D, Chyau C-C et al. Supercritical fluid extracts of rosemary leaves exhibit potent anti-inflammation and anti-tumor effects. *Biosci. Biotechnol. Biochem.* 71(9), 2223–2232 (2007).

103. Zanella CA, Treichel H, Cansian RL, Roman SS. The effects of acute administration of the hydroalcoholic extract of rosemary (*Rosmarinus officinalis* L.) in animal models of memory. *Brazilian J. Pharm. Sci.* 48(3), 389–397 (2012).

104. Martinez AL, Gonzalez-Trujano ME, Chavez M, Pellicer F. Antinociceptive effectiveness of triterpenes from rosemary in visceral nociception. *J. Ethnopharmacol.* 142(1), 28–34 (2012).

105. Rosenbaum CC, O’Mathúna DP, Chavez M, Shields K. Antioxidants and antiinflammatory dietary supplements for osteoarthritis and rheumatoid arthritis. *Altern. Ther. Health Med.* 16(2), 32–40 (2010).

106. Kuo C-F, Su J-D, Chiu C-H et al. Anti-inflammatory effects of supercritical carbon dioxide extract and its isolated carnosic acid from *Rosmarinus officinalis* leaves. *J. Agric. Food Chem.* 59(8), 3674–3685 (2011).

107. Chae IG, Yu MH, Im N-K et al. Effect of *Rosmarinus officinalis* L. on MMP-9, MCP-1 levels, and cell migration in RAW 264.7 and smooth muscle cells. *J. Med. Food.* 15(10), 879–886 (2012).

108. Yu Y-M, Lin H-C, Chang W-C. Carnosic acid prevents the migration of human aortic smooth muscle cells by inhibiting the activation and expression of matrix metalloproteinase-9. *Br. J. Nutr.* 100(4), 731–738 (2008).

109. Lucarini R, Bernardes WA, Ferreira DS et al. In vivo analgesic and anti-inflammatory activities of *Rosmarinus officinalis* aqueous extracts, rosmarinic acid and its acetyl ester derivative. *Pharm. Biol.* 51(9), 1087–1090 (2013).

110. Lukacz D, Darland G, Tripp M et al. A Pilot trial evaluating meta050, a proprietary combination of reduced iso-alpha acids, rosemary extract and oleic acid in patients with arthritis and fibromyalgia. *Phytother. Res.* 19(10), 864–869 (2005).

111. Minich DM, Bland JS, Katke J et al. Clinical safety and efficacy of NG440: a novel combination of rho iso-alpha acids from hops, rosemary, and oleic acid for inflammatory conditions. *Can. J. Physiol. Pharmacol.* 85(9), 872–883 (2007).

112. Rahimifard M, Navaei-Nigjeh M, Mahroui N et al. Improvement in the function of isolated rat pancreatic islets through reduction of oxidative stress using traditional Iranian medicine. *Cell J.* 16(2), 147–163 (2014).

113. Tu Z, Moss-Pierce T, Ford P, Jiang TA. Rosemary (*Rosmarinus officinalis* L.) extract regulates glucose and lipid metabolism by activating AMPK and PPAR pathways in HepG2 cells. *J. Agric. Food Chem.* 61(11), 2803–2810 (2013).

114. Ozarowski M, Mikolajczak PL, Bogacz A et al. *Rosmarinus officinalis* L. leaf extract improves memory impairment and affects acetylcholinesterase and butyrylcholinesterase activities in rat brain. *Fitoterapia.* 91, 261–271 (2013).

115. Sasaki K, El Omri A, Kondo S, Han J, Isoda H. *Rosmarinus officinalis* polyphenols produce anti-depressant like effect through monoaminergic and cholinergic functions modulation. *Behav. Brain Res.* 238, 86–94 (2013).

116. Machado DG, Canha MP, Neis VB et al. Antidepressant-like effects of fractions, essential oil, carnosol and betulinic acid isolated from *Rosmarinus officinalis* L. *Food Chem.* 136(2), 999–1005 (2013).

117. El Omri A, Han J, Ben Abdraham M, Isoda H. Down regulation effect of *Rosmarinus officinalis* polyphenols on cellular stress proteins in rat pheochromocytoma PC12 cells. *Cytotechnology* 64(3), 231–240 (2012).

118. Pengelly A, Snow J, Mills SY, Scholey A, Westnes K, Butler LR. Short-term study on the effects of rosemary on cognitive function in an elderly population. *J. Med. Food.* 15(1), 10–17 (2012).
119. Bone K, Mills S. *Principles and Practice of Phytotherapy: Modern Herbal Medicine*. Elsevier Health Sciences, Edinburgh, UK (2013).
